CEL001 injection safety study for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new injection called CEL001 for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if it is safe and find the right dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your tumor must be advanced and standard treatments have stopped working or caused too many side effects.
- You need to have at least one tumor that can be measured on scans.
- Your blood counts, liver, and kidney function must meet certain levels.
- You must not have had cancer treatment (like chemo or radiation) in the past 4 weeks.
- You cannot have had immunotherapy before or have a history of autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new drug (CD-001) for people with advanced solid tumors. It will check if the drug is safe, how the body handles it, and if it helps shrink tumors.
This study tests an investigational cell therapy (GK01) for people with advanced solid tumors that have grown despite standard treatment or have no standard treatment option. It may help shrink tumors or slow their growth.
This trial tests an experimental cell therapy (HS-IT101) for people with advanced solid tumors that have not responded to standard treatments. It uses immune cells from your own tumor to fight cancer, and researchers want to see if it is safe and effective.
This trial tests an investigational NK cell therapy (NK042) for people with advanced solid tumors that have not responded to standard treatments. The aim is to see if this cellular therapy is safe and potentially effective.
This trial tests an investigational cell therapy called GKL-006Allo for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can help shrink or slow the growth of tumors.
This trial tests an experimental treatment called GK01, which uses your own immune cells (called tumor-infiltrating lymphocytes) that have been taken from your tumor, multiplied in a lab, and given back to you. It is for people with advanced solid tumors that have not responded to standard treatments, and aims to see if these cells can shrink your cancer.
Hear when a new Advanced Solid Tumors (Phase 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.